Skip to main contentSkip to navigationSkip to search
ENZY  
SEK  %
Logotype
ENZY  
SEK  %
Logotype

Media

Press releases

2024

February 16, 2024 - Regulatory press release
Enzymatica’s Board of Directors decides on a new rights issue of SEK 27.4 million

2023

November 30, 2023 - Regulatory press release
Enzymatica changes Certified Adviser to Carnegie Investment Bank AB (publ)
November 7, 2023 - Regulatory press release
Interim report Q3/2023: Research results that reshape the competitive landscape
September 21, 2023 - Regulatory press release
Interim report from clinical study: ColdZyme significantly reduces rhinovirus viral load and symptoms of sore throat
August 22, 2023 - Regulatory press release
New study: ColdZyme breaks viral infection cycle – significantly reducing influenza viral load
July 18, 2023 - Regulatory press release
Interim report Q2/2023: An exciting and important time ahead
May 4, 2023 - Regulatory press release
Bulletin from Annual General Meeting of Enzymatica AB (publ)
April 27, 2023 - Regulatory press release
Interim report Q1/2023: Strong start to the year – Enzymatica’s growth journey continues according to plan
April 5, 2023 - Regulatory press release
Enzymatica publishes annual report for 2022
March 31, 2023 - Regulatory press release
Notice of Annual General Meeting 2023 in Enzymatica AB (publ)
February 17, 2023 - Regulatory press release
Interim report Q4/2022: A year that laid the foundation for growth

2022

November 16, 2022 - Non-regulatory press release
Enzymatica and University of Kent launch study to explore prevention of upper respiratory virus infections in elite athletes
November 2, 2022 - Regulatory press release
Interim report Q3/2022: A broader role for ColdZyme adds potential for the future
November 1, 2022 - Non-regulatory press release
New study confirms ColdZyme stops viruses causing Covid-19 from adhering to human respiratory cells
August 26, 2022 - Regulatory press release
Enzymatica announces outcome of new rights issue
August 18, 2022 - Regulatory press release
Enzymatica publishes supplementary prospectus
August 16, 2022 - Regulatory press release
ColdZyme also blocks omicron variants BA.4 and BA.5
August 5, 2022 - Regulatory press release
Publication of prospectus regarding Enzymatica’s rights issue
July 19, 2022 - Regulatory press release
Interim report Q2/2022: Improved sales give confidence for the future
July 19, 2022 - Regulatory press release
Enzymatica’s Board of Directors decides on a new rights issue of SEK 74.7 million
Load more